AIM: The purpose of this project was to compare the characteristics of two experimental murine models of primary intraocular lymphoma (PIOL) and determine which experimental model is most suitable for further investigational research to elucidate the pathophysiology of PIOL and to find new therapeutical strategies. METHODS: In both experimental models PIOL was induced in immunocompetent mice with intravitreal injection of syngeneic B-cell lymphoma cell lines. Murine strain C3H/HeN and cell line 38C13 were used in the first model and BALB/CaNn mice and cell line A20 in the second model. During the experiments, thorough clinical evaluation (using photo documentation, ultrasonography, and MRI) and histological evaluation were performed. RESULTS: In both models, the percentage of PIOL development was high, reaching nearly 80%. Disease progression was faster in C3H/HeN with exophthalmos occurring on average on day 10. Vitreous involvement was a predominant sign in the clinical presentation of this group. In BALB/CaNn mice exophthalmos occurred on average on day 22. The predominant clinical sign in the BALB/CaNn group was tumorous infiltration of the retina, optic disc, and tumorous retinal detachment. CONCLUSION: Slower progression of the disease in BALB/CaNn mice, greater possibility to examine the retina due to mild vitreous involvement, and later occurrence of exophthalmos makes this strain more suitable for further investigational research.

1st Department of Medicine Department of Haematology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Centre for Advanced Preclinical Imaging 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Ophthalmology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Institute of Histology and Embryology 1st Faculty of Medicine Charles University Prague Czech Republic

Institute of Pathological Physiology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Venkatesh R, Bavaharan B, Mahendradas P, Yadav NK. Primary vitreoretinal lymphoma: prevalence, impact, and management challenges. Clin Ophthalmol 2019;13:353-64. DOI

Tang LJ, Gu CL, Zhang P. Intraocular lymphoma. Int J Ophthalmol 2017;10(8):1301-7.

Sagoo MS, Mehta H, Swampillai AJ, Cohen VM, Amin SZ, Plowman PN, Lightman S. Primary intraocular lymphoma. Surv Ophthalmol 2014;59(5):503-16. DOI

Klimova A, Heissigerova J, Rihova E, Brichova M, Pytlik R, Spicka I, Mrazova K, Karolova J, Svozilkova P. Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse. Br J Ophthalmol 2018;102(11):1579-85. DOI

Chan CC, Fischette M, Shen D, Mahesh SP, Nussenblatt RB, Hochman J. Murine model of primary intraocular lymphoma. Invest Ophthalmol Vis Sci 2005;46(2):415-9. doi: 10.1167/iovs.04-0869 PubMed DOI

Jakša R, Karolová J, Svatoň M, Kazantsev D, Grajciarová M, Pokorná E, Tonar Z, Klánová M, Winkowska L, Maláriková D, Vočková P, Forsterová K, Renešová N, Dolníková A, Nožičková K, Dundr P, Froňková E, Trněný M, Klener P. Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas. Lab Invest 2022;102(9):957-65. DOI

Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, Segal J, Li S, Zhou S, Santos D, Richard S, Sharma S, Chen W, Oriabure O, Liu Y, Huang S, Guo H, Chen Z, Tao W, Li C, Wang J, Fang B, Wang J, Li L, Badillo M, Ahmed M, Thirumurthi S, Huang SY, Shao Y, Lam L, Yi Q, Wang YL, Wang M. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clin Cancer Res 2017;23(15):4212-23. DOI

Rebeaud J, Peter B, Pot C. How Microbiota-Derived Metabolites Link the Gut to the Brain during Neuroinflammation. Int J Mol Sci 2022;23(17):10128. doi: 10.3390/ijms231710128 PubMed DOI

Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol 2019;16(3):137-54. DOI

Aslam H, Green J, Jacka FN, Collier F, Berk M, Pasco J, Dawson SL. Fermented foods, the gut and mental health: a mechanistic overview with implications for depression and anxiety. Nutr Neurosci 2020;23(9):659-71. DOI

Dusek O, Fajstova A, Klimova A, Svozilkova P, Hrncir T, Kverka M, Coufal S, Slemin J, Tlaskalova-Hogenova H, Forrester JV, Heissigerova J. Severity of Experimental Autoimmune Uveitis Is Reduced by Pretreatment with Live Probiotic Escherichia coli Nissle 1917. Cells 2020;10(1):23. doi: 10.3390/cells10010023 PubMed DOI

Li W, Deng Y, Chu Q, Zhang P. Gut microbiome and cancer immunotherapy. Cancer Lett 2019;447:41-7. DOI

Yi M, Jiao D, Qin S, Chu Q, Li A, Wu K. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. Integr Cancer Ther 2019;18:1534735419876351. DOI

Muraro S, Bondanza A, Bellone M, Greenberg PD, Bonini C. Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses. Blood 2005;105(9):3596-3604. DOI

Klimova A, Seidler Stangova P, Svozilkova P, Kucera T, Heissigerova J. The Clinical Signs of Experimental Autoimmune Uveitis. Cesk Slov Oftalmol 2016;72(1):276-82. DOI

Touitou V, Daussy C, Bodaghi B, Camelo S, de Kozak Y, Lehoang P, Naud MC, Varin A, Thillaye-Goldenberg B, Merle-Béral H, Fridman WH, Sautès-Fridman C, Fisson S. Impaired th1/tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma. Invest Ophthalmol Vis Sci 2007;48(7):3223-9. DOI

Seidler Stangova P, Dusek O, Klimova A, Heissigerova J, Kucera T, Svozilkova P. Metronidazole Attenuates the Intensity of Inflammation in Experimental Autoimmune Uveitis. Folia Biol (Praha) 2019;65(5-6):265-74. DOI

Mineo JF, Scheffer A, Karkoutly C, Nouvel L, Kerdraon O, Trauet J, Bordron A, Dessaint JP, Labalette M, Berthou C, Labalette P. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice. Invest Ophthalmol Vis Sci 2008;49(11):4738-45. DOI

Ben Abdelwahed R, Donnou S, Ouakrim H, Crozet L, Cosette J, Jacquet A, Tourais I, Fournès B, Gillard Bocquet M, Miloudi A, Touitou V, Daussy C, Naud MC, Fridman WH, Sautès-Fridman C, Urbain R, Fisson S. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas. Invest Ophthalmol Vis Sci 2013;54(5):3657-65. DOI

Gunduz K, Pulido JS, McCannel CA, O'Neill BP. Ocular manifestations and treatment of central nervous system lymphomas. Neurosurg Focus 2006;21(5):E9. DOI

Aronow ME, Shen D, Hochman J, Chan CC. Intraocular Lymphoma Models. Ocul Oncol Pathol 2015;1(3):214-22. DOI